Trial · NCT01488578
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). | 12 weeks | Safety analysis population included all enrolled subjects who had received at least 1 confirmed, administration of Detrusitol. | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| PRIMARY | Number of Participants Which Was Evaluated as Degree of Satisfaction. | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| PRIMARY | Number of Participants With an Investigator's Assessment of Clinical Outcome at End of the Study. | 12 week | The efficacy analysis population included all subjects from the safety analysis population in whom the efficacy of this drug could be evaluated.~Number of participants evaluable for which was evaluated effect. | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Gender | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Complications | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Age | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy | 12 week | The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| SECONDARY | Number of Unlisted Treatment Related Adverse Events (TRAEs)Reported in at Least 5 Participants | 12 week | Safety analysis population included all enrolled subjects who had received at least 1 confirmed, administration of Detrusitol. | events | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Severity of Overactive Bladder | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinations Per Day (During Sleep) | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Number of Urinary Incontinence Episodes Per Day | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| SECONDARY | Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment | 12 week | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | participants | NUMBER |
| PRIMARY | Confirmation of Frequent Treatment Related Adverse Events (TRAEs) at the End of Observation Period. | 12 week | Safety analysis population included all enrolled subjects who had received at least 1 confirmed, administration of Detrusitol. | events | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01488578/outcomes